Drucker Wealth 3.0 LLC Has $2.10 Million Stake in Johnson & Johnson $JNJ

Key Points

• Drucker Wealth 3.0 LLC increased its stake in Johnson & Johnson by 121%, now owning 13,419 shares valued at approximately $2.1 million.
• Insider activity included EVP Jennifer L. Taubert selling 56,471 shares, decreasing her position by 24.08% after the sale.
• Wall Street analysts have raised their ratings for Johnson & Johnson, with the stock currently holding an average rating of "Moderate Buy" and a consensus price target of $192.94.

Drucker Wealth 3.0 LLC grew its holdings in shares of Johnson & Johnson (NYSE:JNJ - Free Report) by 121.0% in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 13,419 shares of the company's stock after acquiring an additional 7,348 shares during the period. Drucker Wealth 3.0 LLC's holdings in Johnson & Johnson were worth $2,097,000 as of its most recent SEC filing.

A number of other large investors have also recently bought and sold shares of the business. GFG Capital LLC bought a new position in shares of Johnson & Johnson during the 2nd quarter worth about $35,000. Highline Wealth Partners LLC lifted its position in Johnson & Johnson by 51.8% in the 1st quarter. Highline Wealth Partners LLC now owns 252 shares of the company's stock valued at $42,000 after acquiring an additional 86 shares in the last quarter. Stone House Investment Management LLC bought a new position in Johnson & Johnson in the 1st quarter valued at about $47,000. 1248 Management LLC bought a new position in Johnson & Johnson in the 1st quarter valued at about $48,000. Finally, von Borstel & Associates Inc. bought a new position in Johnson & Johnson in the 1st quarter valued at about $49,000. 69.55% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity

In other news, EVP Jennifer L. Taubert sold 56,471 shares of the firm's stock in a transaction that occurred on Thursday, September 4th. The shares were sold at an average price of $177.81, for a total transaction of $10,041,108.51. Following the completion of the sale, the executive vice president owned 178,013 shares in the company, valued at $31,652,491.53. This trade represents a 24.08% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. 0.16% of the stock is currently owned by insiders.

Wall Street Analysts Forecast Growth

JNJ has been the topic of several recent research reports. Erste Group Bank raised shares of Johnson & Johnson from a "hold" rating to a "buy" rating in a research report on Wednesday, July 23rd. Royal Bank Of Canada reaffirmed an "outperform" rating and issued a $209.00 price target on shares of Johnson & Johnson in a research report on Friday. Piper Sandler reaffirmed an "overweight" rating on shares of Johnson & Johnson in a research report on Thursday, July 17th. Guggenheim raised shares of Johnson & Johnson from a "neutral" rating to a "buy" rating and raised their price target for the company from $167.00 to $206.00 in a research report on Tuesday, September 23rd. Finally, Wells Fargo & Company set a $212.00 target price on shares of Johnson & Johnson and gave the stock an "overweight" rating in a research report on Friday, October 3rd. Two research analysts have rated the stock with a Strong Buy rating, twelve have assigned a Buy rating and eight have given a Hold rating to the company. According to data from MarketBeat.com, Johnson & Johnson currently has an average rating of "Moderate Buy" and a consensus price target of $192.94.

Johnson & Johnson Price Performance

Johnson & Johnson stock opened at $190.66 on Monday. Johnson & Johnson has a 52 week low of $140.68 and a 52 week high of $192.10. The company's 50 day moving average price is $178.48 and its two-hundred day moving average price is $163.78. The company has a quick ratio of 0.76, a current ratio of 1.01 and a debt-to-equity ratio of 0.50. The stock has a market cap of $459.16 billion, a P/E ratio of 20.39, a P/E/G ratio of 2.40 and a beta of 0.40.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last issued its quarterly earnings results on Wednesday, August 30th. The company reported $2.26 earnings per share (EPS) for the quarter. Johnson & Johnson had a net margin of 25.00% and a return on equity of 32.49%. The company had revenue of $24.02 billion during the quarter. On average, equities analysts predict that Johnson & Johnson will post 10.58 earnings per share for the current year.

Johnson & Johnson Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Tuesday, September 9th. Stockholders of record on Tuesday, August 26th were paid a dividend of $1.30 per share. The ex-dividend date was Tuesday, August 26th. This represents a $5.20 annualized dividend and a dividend yield of 2.7%. Johnson & Johnson's dividend payout ratio (DPR) is presently 55.61%.

About Johnson & Johnson

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.